Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/17/2025

Urinary Tract Infections in Patients with Ureteral Stents

Introduction to Treatment

  • The European Association of Urology recommends a 2 gm dose of ceftriaxone for complicated UTIs, which achieves sufficient free plasma concentration to treat even resistant strains 2
  • Ceftriaxone 2 gm IV is sufficient for treating a urinary tract infection in a patient with a ureteral stent, as this dosage has been shown to effectively cover common uropathogens and reduce serious post-procedural sepsis-related complications from 50% to 9% in high-risk patients 1
  • Up to 50% of ureteral stent infections can be polymicrobial, requiring broad-spectrum coverage that ceftriaxone provides 1

Administration and Monitoring

  • Once-daily dosing of ceftriaxone is appropriate for stent-associated infections 1
  • Clinical improvement should be evident within 48-72 hours, and consider imaging if no improvement after 72 hours 2
  • Obtain cultures before initiating therapy if possible, to guide targeted therapy if initial empiric treatment fails

Alternative Therapies

  • For ceftriaxone-resistant infections, options include ertapenem 1 gm IV daily 3
  • Piperacillin/tazobactam 2.5-4.5 g TID is an alternative therapy for ceftriaxone-resistant infections 2
  • Carbapenems can be used for multidrug-resistant organisms 2

Prevention Strategies

  • Maintain clean exit site with antiseptics, and perform regular dressing changes to prevent infection 1
  • Avoid concomitant use of Foley catheters with ureteral stents when possible, and periodically reassess the need for the stent, as duration of placement is a key risk factor for infection 1